Conversa Health is a technology company.
Conversa Health has raised $29.0M across 3 funding rounds.
Key people at Conversa Health.
Conversa Health has raised $29.0M in total across 3 funding rounds.
Conversa Health has raised $29.0M in total across 3 funding rounds.
Conversa Health's investors include Advisors Fund LLC, Better Ventures, Builders VC, Mayfield, Arkitekt Ventures, Curie.Bio, Khosla Ventures, Operator Partners, Assaf Wand.
Conversa Health is a healthcare technology company that developed an Automated Virtual Care and Triage™ platform, leveraging proprietary patient profiling, health signals analysis, and evidence-based conversational care pathways to enable remote patient management across the care continuum[1][2][3]. It serves health systems, payers, employers, and pharmaceutical companies—such as Northwell Health, UCSF Health, UNC Health, and University Hospitals—by automating patient outreach, risk stratification, data collection from EHRs and devices, and triage to appropriate care levels like telehealth or in-person visits, addressing gaps in between-visit monitoring for chronic conditions, post-acute care, oncology, pediatrics, and more[1][2][3][5]. The platform drove strong growth, especially during COVID-19 with rapid scaling of specialized programs, before its acquisition by Amwell in July 2021 after raising $32.5M in funding[4][6].
Founded in 2014 in Portland, Oregon, Conversa Health was led by Murray Brozinsky as CEO, an innovative entrepreneur with a track record in healthcare innovation who frequently keynoted at events like the World Medical Innovation Forum[2][3]. The idea emerged from recognizing that healthcare providers lacked insights into patients' conditions between visits, despite patients generating valuable health data; Brozinsky's team built a platform to automate outreach via conversational AI, collect biometrics and self-reports, analyze risks, and provide personalized guidance—pioneering "Automated Virtual Care"[3]. Early traction built through an expanding library of over 330 clinically intelligent programs for conditions like asthma, COPD, CHF, diabetes, and joint replacement, with pivotal acceleration during COVID-19 when the team leveraged existing tech and health system relationships to launch targeted products, fueling massive 2020 growth[5][6].
Conversa rode the virtual care and digital health wave, particularly accelerated by COVID-19, which highlighted needs for scalable, automated solutions amid overwhelmed systems and a shift to remote monitoring[2][6]. Its timing capitalized on rising adoption of AI for population health management, predictive triage, and patient-generated data, aligning with market forces like value-based care, chronic disease burdens, and demands for equitable, affordable access—positioning it ahead of competitors like Diagnostic Robotics, Mediktor, and Infermedica in conversational automation[4]. By enabling health systems to extend care 24/7 and integrate with ecosystems, Conversa influenced the sector toward AI-augmented models, enhancing outcomes and efficiency; its Amwell acquisition amplified this, embedding automated triage into larger telehealth platforms[4][5].
Post-2021 Amwell acquisition, Conversa Health's platform likely continues evolving within Amwell's ecosystem, integrating deeper AI for expanded virtual care amid ongoing trends like AI-driven personalization, RPM growth, and hybrid care models[4]. Rising demands for cost-effective chronic management and post-pandemic telehealth normalization will shape its trajectory, potentially broadening to global payers and pharma while leveraging Amwell's scale for innovation in predictive analytics. As a pioneer in automated triage, its influence could grow by setting standards for conversational AI in health, driving broader ecosystem shifts toward proactive, data-rich patient engagement—reinforcing its role as a game-changer in accessible care delivery[2][5].
Key people at Conversa Health.
Conversa Health has raised $29.0M across 3 funding rounds. Most recently, it raised $8.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $8.0M Series B | Advisors Fund LLC, Better Ventures, Builders VC, Mayfield | |
| Jun 1, 2020 | $12.0M Series B | Advisors Fund LLC, Arkitekt Ventures, Better Ventures, Builders VC, Curie.Bio, Khosla Ventures, Mayfield, Operator Partners, Assaf Wand | |
| May 1, 2017 | $9.0M Series A |
